- Published
- 18 June 2021
- Journal article
Adapted treatment of ANCA-associated vasculitis during the COVID-19 pandemic
- Authors
- Source
- Rheumatology Advances in Practice
Full text
Abstract
The ANCA-associated vasculitides (AAV) are multisystem diseases presenting with wide-ranging symptoms and, frequently, a long prodrome of malaise before diagnosis. We observed that patterns of presentation with AAV altered during the coronavirus disease 2019 (COVID-19) pandemic, and consideration of the infection risk led us to change our treatment of the disease. We report the outcomes of patients with AAV with kidney involvement at a tertiary renal unit in the UK, covering a population of 1.6 million. We observed only one de novo presentation of AAV during the first lockdown in March–June 2020, followed by 11 cases in the latter part of the year (nine MPO-ANCA and two PR3-ANCA), including five during the second lockdown from November to December 2020.
Rights
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cite as
Nimmo, A. & Risdale, S. 2021, 'Adapted treatment of ANCA-associated vasculitis during the COVID-19 pandemic', Rheumatology Advances in Practice, 5(2), article no: rkab041. https://doi.org/10.1093/rap/rkab041